European Medical Journal

Universal Cytomegalovirus Screening Detects Hidden Newborn Infections

A 3-year study in Israel shows pooled-saliva congenital cytomegalovirus universal screening identifies hidden infections in ...
Adelaide Now

Hidden pregnancy virus: Why experts want all parents to know about CMV

While pregnant women know the consequences of soft cheese and raw meat, they're rarely warned about a virus 30 times more common that could devastate their unborn child. I didn’t know what those three ...
The Malaysian Reserve

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...
Targeted Oncology

Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL

Odronextamab combined with CHOP showed high efficacy in untreated DLBCL, with a 100% response rate at the 160 mg dose. The safety profile was manageable, with no new safety signals, and most patients ...
The American Journal of Managed Care

Orlowski Calls Linvoseltamab Results “the Best Single Agent Data Ever In the History of Myeloma”

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...